Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04271397` - Immunological Biomarkers in Tuberculosis Management	N/A
Completed	`NCT04545164` - Computer Aided Screening for Tuberculosis in Low Resource Environments	N/A
Recruiting	`NCT05766267` - Short-course Regimens for the Treatment of Pulmonary Tuberculosis	Phase 2/Phase 3
Recruiting	`NCT05756582` - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Enrolling by invitation	`NCT04988984` - Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
Recruiting	`NCT04148053` - Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Recruiting	`NCT01689831` - Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)	Phase 2
Completed	`NCT05945498` - Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years	Phase 1
Not yet recruiting	`NCT06352970` - Effects of Tuberculosis Infection on Development and Function of the Placenta
Recruiting	`NCT04575519` - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis	Phase 2
Recruiting	`NCT03941210` - Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
Completed	`NCT04494516` - Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
Withdrawn	`NCT03265977` - A Phase II Study of H56:IC31 in Healthy Adolescents	Phase 2
Recruiting	`NCT05069688` - Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin	Phase 1
Suspended	`NCT05330884` - BCG Revaccination in Children and Adolescents	Phase 3
Recruiting	`NCT05342064` - Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service	N/A
Recruiting	`NCT05236452` - Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection	N/A
Recruiting	`NCT05443178` - Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy	Phase 1
Recruiting	`NCT05122026` - Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV	Phase 1/Phase 2
Recruiting	`NCT06221488` - Testing Health Workers At Risk to Advance Our Understanding of TB Infection

NCT number	NCT05413551
Study type	Interventional
Source	Stanford University
Contact
Status	Recruiting
Phase	Phase 1
Start date	March 23, 2023
Completion date	September 30, 2024

Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms